Neoplastic transformation in tissues of rats exposed to monocrotaline or dehydroretronecine

R. C. Shumaker, Kent Robertson, I. C. Hsu, J. R. Allen

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Male Sprague Dawley rats received sc injections biweekly of either the pyrrolizidine alkaloid monocrotaline or its metabolite dehydroretronecine for 1 year. The animals were then observed for an additional 12 months for the induction of neoplasms. Of 60 rats that received dehydroretronecine, 39 developed rhabdomyosarcomas at the injection site, and 5 of these neoplasms metastasized. In the 60 monocrotaline treated rats, 31 widely dispersed tumors of various cell types were recorded. The reason suggested for the variation in tissue response was that the metabolite dehydroretronecine is a proximate carcinogen, whereas monocrotaline must first be metabolized before its carcinogenic potential is realized.

Original languageEnglish (US)
Pages (from-to)787-790
Number of pages4
JournalJournal of the National Cancer Institute
Volume56
Issue number4
StatePublished - 1976
Externally publishedYes

Fingerprint

Monocrotaline
Neoplasms by Site
Pyrrolizidine Alkaloids
Injections
Rhabdomyosarcoma
Carcinogens
Sprague Dawley Rats
Neoplasms
dehydroretronecine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Neoplastic transformation in tissues of rats exposed to monocrotaline or dehydroretronecine. / Shumaker, R. C.; Robertson, Kent; Hsu, I. C.; Allen, J. R.

In: Journal of the National Cancer Institute, Vol. 56, No. 4, 1976, p. 787-790.

Research output: Contribution to journalArticle

@article{35542154a19c4745bbd3ee3ff25d824a,
title = "Neoplastic transformation in tissues of rats exposed to monocrotaline or dehydroretronecine",
abstract = "Male Sprague Dawley rats received sc injections biweekly of either the pyrrolizidine alkaloid monocrotaline or its metabolite dehydroretronecine for 1 year. The animals were then observed for an additional 12 months for the induction of neoplasms. Of 60 rats that received dehydroretronecine, 39 developed rhabdomyosarcomas at the injection site, and 5 of these neoplasms metastasized. In the 60 monocrotaline treated rats, 31 widely dispersed tumors of various cell types were recorded. The reason suggested for the variation in tissue response was that the metabolite dehydroretronecine is a proximate carcinogen, whereas monocrotaline must first be metabolized before its carcinogenic potential is realized.",
author = "Shumaker, {R. C.} and Kent Robertson and Hsu, {I. C.} and Allen, {J. R.}",
year = "1976",
language = "English (US)",
volume = "56",
pages = "787--790",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Neoplastic transformation in tissues of rats exposed to monocrotaline or dehydroretronecine

AU - Shumaker, R. C.

AU - Robertson, Kent

AU - Hsu, I. C.

AU - Allen, J. R.

PY - 1976

Y1 - 1976

N2 - Male Sprague Dawley rats received sc injections biweekly of either the pyrrolizidine alkaloid monocrotaline or its metabolite dehydroretronecine for 1 year. The animals were then observed for an additional 12 months for the induction of neoplasms. Of 60 rats that received dehydroretronecine, 39 developed rhabdomyosarcomas at the injection site, and 5 of these neoplasms metastasized. In the 60 monocrotaline treated rats, 31 widely dispersed tumors of various cell types were recorded. The reason suggested for the variation in tissue response was that the metabolite dehydroretronecine is a proximate carcinogen, whereas monocrotaline must first be metabolized before its carcinogenic potential is realized.

AB - Male Sprague Dawley rats received sc injections biweekly of either the pyrrolizidine alkaloid monocrotaline or its metabolite dehydroretronecine for 1 year. The animals were then observed for an additional 12 months for the induction of neoplasms. Of 60 rats that received dehydroretronecine, 39 developed rhabdomyosarcomas at the injection site, and 5 of these neoplasms metastasized. In the 60 monocrotaline treated rats, 31 widely dispersed tumors of various cell types were recorded. The reason suggested for the variation in tissue response was that the metabolite dehydroretronecine is a proximate carcinogen, whereas monocrotaline must first be metabolized before its carcinogenic potential is realized.

UR - http://www.scopus.com/inward/record.url?scp=0017129381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017129381&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 787

EP - 790

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 4

ER -